The Peptide Pandemic

Written by Nadia Malik, Independent Prescriber, Pharmacist, CVRM

The proliferation of peptide content across social media platforms is impossible to ignore. Self-proclaimed biohackers (who are not healthcare professionals) promote compounds marked "for research purposes only." This label takes advantage of a legal loophole. It also normalises self-experimentation with active substances. Bodybuilding culture has now entered the mainstream health and wellness scene. Yet, there is a noticeable lack of regulatory response.

The scale of the shift is significant. More than two million people in the UK use GLP-1 receptor agonists; however, fewer than 500,000 get them through NHS prescriptions.¹ When Eli Lilly announced a 170% price hike for Mounjaro in the UK in August 2025, many quickly turned to unregulated alternatives.² Restricted access and commercial pricing did not suppress demand, it redirected it.

The legal position is often misunderstood. Peptides are not categorically illegal. A regulatory loophole allows their sale for "research purposes only." This keeps suppliers safe and creates a visible market, but it operates outside any clinical governance framework. The landscape is heterogenous. Some compounds have solid mechanistic data and animal evidence. Others lack any human safety data.

The success of licensed peptide-based medicines like insulin, semaglutide, and tirzepatide has created a halo effect. People now think that since some peptides work, all peptides must work too. What these biohackers fail to articulate or understand is that each compound carries its own distinct amino acid sequence, receptor binding profile, and biological behaviour. The evidence for one peptide confers no meaningful insight into the safety or efficacy of another, and only a scant few within any broader therapeutic class have achieved clinically approved use ^3,4.

The grey market peptide trade operates globally, with supply chains originating predominantly from manufacturers in China. Distributed by domestic grey market suppliers in the UK, US, Australia, and Europe ⁵.

The regulatory response is also fragmented. The FDA, MHRA, and EMA work under different laws. This creates gaps that suppliers can easily exploit.

In the UK, the MHRA is investigating clinics that make unsubstantiated claims about peptide therapies. Meanwhile, in the US, the FDA has found serious safety risks with at least 18 common peptide components ^6,7.

The dangers are not limited to the pharmacological effects of the compounds themselves:

• A Belgian forensic analysis found that some injectable peptides from illegal online pharmacies had purity as low as 5%. Additionally, arsenic and lead levels were above ICH safety limits. Notably, the arsenic detected was in its more toxic inorganic form ⁸.

• Bacterial endotoxins, introduced through non-sterile manufacturing environments, represent a serious and under-appreciated clinical risk; entirely independent of whatever the compound is intended to do.

• The scale of harm is significant. By November 2024, the FDA received 392 reports of adverse events linked to compounded semaglutide and 215 for compounded tirzepatide. These include severe hypoglycaemia and serious gastrointestinal issues ⁹.

• In July 2025, two women fell critically ill after getting peptide injections at an anti-ageing conference in Las Vegas. Both needed hospitalisation; one was intubated. Investigators found that at least one component had an existing FDA safety warning.¹⁰

• Closer to home, the MHRA's Criminal Enforcement Unit launched investigations following 41 confirmed cases of botulism between June and August 2025. These cases were connected to unlicensed injectable products given in unregulated settings ¹¹

The peptide market is not an abstract regulatory concern, it is generating real clinical harm.

The clinical community needs to recognise that, in many cases, the grey market came before formal medicine. Semaglutide was used in performance communities for body composition before it got regulatory approval for obesity ¹². The pharmacological rationale was understood by users. Pharmaceutical approval formalised what unregulated use had already established.

Stacking different compounds to personalise outcomes is a basic step towards precision medicine. It customises receptor targets and dosing intervals, something formal pharmacology is just starting to recognise. This approach is crowd-sourced from social media, forum threads, and self-reported outcomes. It isn’t conceptually inferior; it’s just unvalidated, which is an important difference.

The grey market was stacking GLP-1 agonists with amylin analogues and growth hormone secretagogues years before pharma formalised the concept. Novo Nordisk's CagriSema— combining semaglutide with the amylin receptor agonist cagrilintide, submitted to the FDA in December 2025 — is the licensed articulation of what bodybuilding forums had already operationalised through self-directed trial and error ¹³.

Central to this debate is the notion that pharmaceutical companies only research and patent what they can profit from. FDA approval for a novel compound costs in the region of one billion dollars and takes the better part of a decade ¹⁴. Composition patents run for twenty years from filing — meaning that by the time an older, well-characterised peptide cleared a regulatory pathway, meaningful patent protection would already have elapsed and commercial exclusivity with it ¹⁵. No exclusivity means no return on investment. Companies do not run billion-dollar trials on molecules they cannot profitably sell ¹⁶.

• Semaglutide exists as a licensed product because it could be patented, manufactured at scale, and priced to return investment.

BPC-157, one of the most widely used grey market peptides, has been under patent since 1989, held by a small Croatian research group — but with trials costing upwards of $500 million, no major pharmaceutical company has any commercial incentive to develop a molecule it did not originate and cannot profitably protect ^17,18. The lack of robust evidence supporting grey market peptides is not necessarily proof of danger. It shows a market failure in research funding. The current regulations don’t recognise this, and patients can't easily understand it.

The retatrutide case illustrates where this trajectory leads. In late 2024, Eli Lilly aimed for biologic classification for retatrutide at the FDA. This designation would extend market exclusivity, take it out of compounding frameworks, and support higher prices…

The FDA declined.

Lilly pursued litigation.

A December 2025 court ruling vacated the agency's decision without resolving the classification, returning the matter to the FDA. Lilly escalated to the Seventh Circuit in March 2026; the outcome remains pending ¹⁹.

The market did not wait for resolution. When the FDA revoked access to compounded tirzepatide, grey market users didn’t go back to licensed options. Instead, they moved straight to retatrutide. Research-grade peptide suppliers reported substantial demand increases ¹⁹. The lesson for pharmaceutical strategy was unambiguous: patients with unmet needs will seek out and find alternatives, regardless of what regulations say.

The patient navigating this landscape (partially informed but excluded from licensed pathways by cost or commissioning criteria) is not an outlier. They are a predictable consequence of a system in which drug classification, pricing strategy, and access policy operate on entirely separate timelines with no obligation to align.

The grey market did not create this demand but is most certainly fulfilling it.

References

1. NHS England. Medicines optimisation: GLP-1 receptor agonist prescribing data 2024–25. London: NHS England; 2025.

2. Kelland K. Eli Lilly to hike UK price of Mounjaroweight-loss, diabetes medicines by 170%. Reuters [Internet]. 2025 Aug 14 [cited 2026 May 7]. Available from: https://www.reuters.com

3. Wadman M. The peptide problem: hype is outrunning the evidence. The Conversation [Internet]. 2026 May [cited 2026 May 7]. Available from: https://theconversation.com/the-peptide-problem-hype-is-outrunning-the-evidence-280715

4. Uhlig T, Kyprianou T, Martinelli FG, Oppici CA, Heiligers D, Hills D, et al. The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA Open Proteom. 2014;4:58–69.

5. Maitland-Jones M. Biohacking, peptides, and the grey market. Observer Research Foundation [Internet]. 2026 Apr [cited 2026 May 7]. Available from: https://www.orfonline.org/expert-speak/biohacking-peptides-and-the-grey-market

6. MHRA. MHRA probes UK clinics over unlawful peptide health claims. London: Medicines and Healthcare products Regulatory Agency; 2026.

7. US Food and Drug Administration. FDA identifies significant safety risks with compounded peptide components. Silver Spring (MD): FDA; 2025.

8. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795–807. doi:10.1016/j.talanta.2018.06.023. PMID: 30029448.

9. US Food and Drug Administration. Adverse event reports: compounded semaglutide and tirzepatide. Silver Spring (MD): FDA; 2024.

10. Damon A. A Las Vegas festival promised ways to cheat death. Two attendees left fighting for their lives. ProPublica [Internet]. 2025 Jul 30 [cited 2026 May 7]. Available from: https://www.propublica.org

11. MHRA. MHRA crackdown on illegal 'Botox' after victims left seriously ill. London: Medicines and Healthcare products Regulatory Agency; 2025 Sep.

12. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.

13. Katella K. New GLP-1 weight-loss drugs are coming — and they're stronger than Wegovy and Zepbound. Scientific American [Internet]. 2026 Mar [cited 2026 May 7]. Available from: https://www.scientificamerican.com

14. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.

15. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20(Suppl3):11–29.

16. Neural Nexus. Peptide regulations are changing. Again. [Internet]. 2026 Apr [cited 2026 May 7]. Available from: https://blog.neuralnexus.press

17. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18(2):185.

18. US Patent No. 5,288,708. Body protection compound isolated from gastric juice. United States Patent and Trademark Office; 1994.

19. Eli Lilly and Company v US Food and Drug Administration. Retatrutide biologic classification dispute. United States Court of Appeals, Seventh Circuit; 2026.

Medicine Central is a clinical evidence review for UK primary care clinicians. Content reflects evidence current at time of publication and should be read alongside local formulary and clinical guidance. Guest contributors retain responsibility for the accuracy and originality of their work. Views expressed are the author's own and do not necessarily reflect those of Medicine Central. For healthcare professionals only.